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Abstract
We recently reported the introduction of oncogene-expressing avian retroviruses into somatic mammary cells in
mice susceptible to infection by transgenic expression of tva, encoding the receptor for subgroup A avian leukosis–
sarcoma virus (ALSV). Because ALSV-based vectors poorly infect nondividing cells, they are inadequate for
studying carcinogenesis initiated from nonproliferative cells (e.g., stem cells). Lentivirus pseudotyped with the enve-
lope protein of ALSV infects nondividing TVA-producing cells in culture but has not previously been tested for intro-
ducing genes in vivo. Here, we demonstrate that these vectors infected mammary cells in vivowhen injected into the
mammary ductal lumen of mice expressing tva under the control of the keratin 19 promoter. Furthermore, intraductal
injection of this lentiviral vector carrying the polyoma middle T antigen gene induced atypical ductal hyperplasia and
ductal carcinoma in situ–like premalignant lesions in 30 days and palpable invasive tumors at a median latency of 3.3
months. Induced tumors were a mixed epithelial/myoepithelial histologic diagnosis, occasionally displayed squa-
mous metaplasia, and were estrogen receptor–negative. This work demonstrates the first use of a lentiviral vector
to introduce oncogenes for modeling cancer in mice, and this vector system may be especially suitable for introduc-
ing genetic alterations into quiescent cells in vivo.
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Introduction
The breast epithelium is composed of an inner layer of luminal
epithelial cells and an outer layer of myoepithelial (or basal) cells
[1]. The breast epithelium also harbors stem cells and their daughter
multipotent progenitor cells, which are precursors to these more dif-
ferentiated epithelial and myoepithelial cells; the exact number and
precise location of mammary stem and multipotent progenitor cells
in the epithelium are still controversial [2]. Accumulation of genetic
and epigenetic mutations in the epithelium leads to breast cancer,
and many mutations and estrogen signaling have been associated
with breast cancer. However, it is still unclear how genetic and
epigenetic lesions transform normal breast cells into cancerous cells
in vivo, and whether certain cells in the breast are more vulnerable to
carcinogenic insult than other cells.
Abbreviations: ALSV, avian leukosis–sarcoma virus; BrdU, 5-bromo-2′-deoxyuridine;
ERα, estrogen receptor α; GFP, green fluorescent protein; HA, hemagglutinin; IU, in-
fectious unit; K19, keratin 19; PyMT, polyoma middle T antigen; RCAS, replication-
competent avian leukosis virus with splice acceptor
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Mouse models have been invaluable in our efforts to understand
the cellular and molecular mechanisms of breast carcinogenesis [3].
Chemical carcinogenesis, virus- or transposon-mediated mutagenesis,
and transgenic and knockout models have all helped advance our
knowledge of breast cancer initiation and progression [3,4]. Recently,
we reported a new method of creating mouse models of breast cancer
using RCASBP/A (replication-competent ALV LTR with a splice
acceptor, Bryan polymerase, subgroup A; referred to as RCAS hence-
forth) derived from the subgroup A avian leukosis–sarcoma virus
(ALSV) to deliver oncogenes into a small number of mammary
epithelial cells in transgenic mice expressing the viral receptor, tva,
behind tissue-specific promoters [5]. Before our report, this viral
method had been used to induce tumorigenesis after postnatal onco-
gene delivery to several other organs including the cancers of the
brain [6,7], ovary [8], vascular endothelium [9], pancreas [10], liver
[11], and other cell types [12,13] after the initial report using RCAS
for introducing genes into myoblast cells in mice [14].
RCAS infect nondividing cells with a much reduced efficiency and
cannot stably carry an insert larger than approximately 2.5 kb [15].
To overcome these limitations, Lewis et al. [16] reported a lentiviral
vector that was pseudotyped with the envelope protein of ALSV sub-
group A and demonstrated that this pseudotyped lentiviral vector
could infect 293 cells and cell cycle–arrested mouse embryo fibro-
blasts that express tva. However, it is not known whether such a vec-
tor can be used for in vivo gene delivery and tumor initiation.
Here, we demonstrate that pseudotyped lentiviral vectors can in-
fect mouse cells in vivo. Furthermore, delivery of lentiviral vectors
encoding the mouse polyoma virus middle T antigen (PyMT) into
the mammary glands of transgenic mice expressing tva under the
control of the epithelial keratin 19 promoter resulted in the forma-
tion of invasive mammary tumors. Thus, ALSV-pseudotyped lenti-
viral vectors are suitable for tumor development studies in vivo.
Materials and Methods
Mice
Transgenic mice (on a mixture of FVB and 129 backgrounds) ex-
pressing tva under the control of the keratin 19 promoter have been
reported [17]. These mice (K19-tva) also contained loxP sites in-
serted into the p53 locus for unrelated reasons [18]. Transgenic mice
(on the FVB background) expressing tva from the MMTV LTR
(MMTV-tva) have also been described [5]. All mice were kept on
a diet of PicoLab standard rodent feed #5053 (Purina, St. Louis, MO).
All procedures using mice were performed in compliance with an Insti-
tutional Animal Care and Use Committee–approved animal protocol.
Virus Production
To generate ALSV env-pseudotyped HIV virus for green fluores-
cent protein (GFP) expression (HIV(ALSV)-GFP), ∼50% confluent
293T cells grown in DMEM (Gibco, Invitrogen, Carlsbad, CA) con-
taining 10% fetal bovine serum (Gibco) plus penicillin and strepto-
mycin (Gibco) on 15-cm dishes precoated with 0.02% poly-lysine
(BD Biosciences, Bedford, MA) were transfected by calcium phos-
phate precipitation with the following plasmids: 10 μg of HIV
Δ8.9 plasmid (supplying the HIV gag and pol ) [16], 15 μg of
pCB6WTA(env) plasmid (providing the ALSV env) [16], and 10 μg
of HIV backbone plasmid FG-12 (containing the GFP gene to be
packaged in the virus; Figure W1) [19]. The transfected cells were
washed and changed to fresh medium the following day. Viral medium
was harvested 3 or 4 days after transfection. After centrifugation for
5 minutes at 500g to remove cell debris, the virus was concentrated
by ultracentrifugation of the viral medium at 90,000g for 90 minutes.
The resulting 100× viral concentrate was stored in aliquots at −80°C.
The viral titer was determined by limiting dilution in NIH 3T3-TVA
cells; fluorescence microscopy was used to identify the highest dilution
with infectious virus.
To generate ALSV env-pseudotyped HIV virus expressing PyMT
(HIV(ALSV)-PyMT ), we first inserted the coding sequence for PyMT
into the XhoI site of pOZ-FH-C [20] to obtain C-terminal FLAG-
and hemagglutinin (HA)-tagged PyMT. EcoRV was added to both ends
of this tagged PyMT insert using polymerase chain reaction primers
(TCAGCTACGAAGATATCTACCGGTAAGGTGGAC-
CATCCTCTAGA and GTTCTCGAGTCGATATCCACTAGT-
AAATCTCTCGATGCGGCCCTA). The resulting EcoRV fragment
was inserted into the HIV vector (pCS-CG cppt) [16] that had been
cut with NheI and XhoI (New England Biolabs, Ipswich, MA) and
blunted with the Klenow fragment of DNA polymerase I. The result-
ing viral construct (Figure W1) was transfected along with the other
helper plasmids into 293T cells to produce virus as described pre-
viously. The viral titer was determined by limiting dilution in NIH
3T3-TVA cells using immunofluorescence to identify the highest di-
lution point. Of note, addition of HA and FLAG tags did not alter
the transforming potency of PyMT when assayed in cultured rodent
fibroblasts (data not shown), but it is unknown whether this tagged
PyMTmight cause a different immune response than untagged PyMT
in mice.
RCAS-GFP [5] was similarly titered as HIV(ALSV)-GFP. RCAS-
PyMT was made by inserting the tagged PyMT into RCAS and was
titered by limiting dilution in DF1 chicken fibroblasts followed by
Western blot analysis.
Intraductal Injection
The up-the-teat injection method [21] was used with modifica-
tions. Mice were anesthetized, mammary ducts were exposed by
removal of nipple ends, and a Hamilton syringe equipped with a
33-gauge needle (Hamilton, Reno, NV) was used to inject 10 μl of
viral concentrate into the ductal lumen of glands #2, 3, and 4. After all
injections into a given mouse were completed, an incision in the ven-
tral skin was made to view the mammary ducts; trace bromophenol
blue (Fisher, Fair Lawn, NJ) added to the concentrate allowed confir-
mation of injection success.
Flow Cytometry
Five days after intraductal injection of HIV(ALSV)-GFP or RCAS-
GFP, infected mammary glands were excised, minced finely by scal-
pel, and digested in DMEM/F-12 medium containing 5% fetal
bovine serum (Gibco), 171 U/ml collagenase (Worthington, Lakewood,
NJ), 100 U/ml hyaluronidase (Sigma, St. Louis, MO), 5 μg/ml in-
sulin (Biosource, Rockville, MD), 500 ng/ml hydrocortisone, and
10 ng/ml epidermal growth factor (Invitrogen, Carlsbad, CA) at
37°C for 1 hour. Cells were then digested in 0.25% trypsin EDTA
(Gibco) for 1 minute, followed by digestion for 5 minutes in 2.4 U/ml
dispase II (Roche, Penzbeg, Germany) + 0.1 mg/ml DNAse
(Worthington). Red blood cells were lysed in NH4Cl, and cells
were passed through a 40-μm filter (BD Falcon, Bedford, MA)
before flow cytometry, which was performed on an EPICS XL-
MCL flow cytometer (Beckman Coulter, Fullerton, CA). In some
experiments, 0.5 μg/ml propidium iodide (Sigma) was added imme-
654 Introducing Oncogenes in Mice with Lentiviral Vector Siwko et al. Neoplasia Vol. 10, No. 7, 2008
diately before flow cytometry to identify dead cells. The resulting
data were analyzed using the EXPO 32 ADC analysis software pack-
age (Beckman Coulter).
Immunohistochemistry
Mammary glands and tumors were fixed in 10% formalin over-
night and embedded in paraffin. Paraffin blocks were sectioned at
3 μm thickness, deparaffinized by serial incubations in xylene (4×)
and graded ethanol solutions (2× 100%; 2× 95%; 1× 75%; 1×
50%), and rinsed in ddH2O. Sections were either hematoxylin and
eosin (H&E)–stained or used for immunohistochemical staining as
follows: Antigen retrieval was performed by simmering in EDTA
buffer (1 mM EDTA, 0.05% Tween 20, pH 8.0) for 15 minutes.
Endogenous peroxidase activity was quenched in 3% H2O2 for
5 minutes. Tissue sections were blocked in either the M.O.M. mouse
IgG blocking reagent or goat serum (Vector Labs, Burlingame, CA),
and then incubated for 1 hour at room temperature with a primary
antibody. Antibodies used include mouse anti-influenza HA (16B12
at 1:500 dilution; Covance, Princeton, NJ), rabbit anti–estrogen re-
ceptor α (ERα) (MC-20 at 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), rat anti–keratin 8 (at 1:100; Developmental Studies Hy-
bridoma Bank, Iowa City, IA), rabbit anti–keratin 5 (AF 138 at
1:1000; Covance), rabbit anti–keratin 14 (AF 64 at 1:100; Covance),
rabbit anti–keratin 6 (PRB 169P at 1:200; Covance), mouse anti–α
smooth muscle actin (1A4 at 1:100; Dako, Glostrup, Germany),
mouse anti-p63 (63P02 at 1:100; NeoMarkers, Fremont, CA), and
mouse anti-BrdU (B44 at 1:100; Becton Dickinson, Franklin Lakes,
NJ). The reactions were amplified with either M.O.M. biotinylated
antimouse IgG or Vectastain biotinylated antirabbit IgG, followed by
detection using Vectastain Elite ABC Reagent with Nova Red as sub-
strate (Vector Labs). Tissues were counterstained in hematoxylin.
Sections were viewed using a microscope (objective, ×20; DMLB;
Leica Microsystems, Wetzlar, Germany), and images were captured
with a digital camera (Optronics, Goleta, CA) using MagnaFire SP
software (Optronics). Tumors were considered estrogen receptor–
positive if 5% or more of total tumor cells produced ERα.
Protein Analysis
Frozen tumor samples were ground to powder in liquid nitrogen,
and proteins were solubilized using M-PER protein extraction re-
agent (Pierce, Rockford, IL) with the addition of a complete protease
inhibitor cocktail (Roche). Protein concentration was determined
using the bicinchoninic acid method (Pierce), and 30 μg of total pro-
tein per sample was run on a sodium dodecyl sulfate gel. Samples
were transferred to nitrocellulose using a Trans-Blot SD apparatus
(Bio-Rad, Hercules, CA), blocked overnight, and probed with a mouse
anti-HA antibody (16B12 at 1:500 dilution; Covance) for 1 hour, fol-
lowed by incubation with an horseradish peroxidase-linked goat anti-
mouse secondary antibody (# 1858413 at 1:5000 dilution; Pierce) for
1 hour. Horseradish peroxidase was detected using Supersignal Pico
chemoluminescent substrate (Pierce). Blots were stripped using Re-
store buffer (Pierce) for 15 minutes at 37°C, blocked and probed as
previously mentioned with a mouse anti–β-actin antibody (1:5000
dilution; Sigma). Quantitation was performed using the FlourChem
8000 software package (Alpha Innotech, San Leandro, CA).
DNA Purification and Southern Hybridization
Tumor DNA (20 μg), purified by proteinase K digestion and
phenol–chloroform extraction, was digested by BamHI, separated
on a 0.7% agarose gel, and transferred to Hybond-N membrane
(GE Healthcare Bio-Sciences Corp, Piscataway, NJ). After UV
cross-linking and prehybridization, the membrane was hybridized
overnight at 68°C to a [α-32P]dCTP (PerkinElmer, Waltham, MA)–
labeled probe transcribed from a 2.4-kb template DNA fragment, ex-
cised from the HIV HA-PyMT plasmid using BamHI and EcoRV. The
RadPrime DNA Labeling System (Invitrogen) was used following the
manufacturer’s instructions. After washing under stringent conditions,
the radioactive bands on the blot were detected using BioMax MR
Film (Kodak, Rochester, NY).
Coimmunofluorescence
Sectioning, deparaffinization, and antigen retrieval were performed
as for immunohistochemical staining previously discussed. After
1 hour of blocking in goat serum, sections were incubated for 1 hour
at room temperature in a primary antibody solution that contained
mouse anti-HA and rabbit anti–keratin 14 (as for immunohis-
tochemistry), and then for 30 minutes at room temperature in a sec-
ondary antibody solution that contained Alexa 568–conjugated goat
antirabbit (A11011 at 1:200; Molecular Probes, Invitrogen) and
fluorescein-conjugated horse antimouse (Fl-2000 at 1:100; Vector
Labs). Stained slides were mounted in Vectashield mounting medium
with 4′-6-diamidino-2-phenylindole (Vector Labs) and examined
under a microscope (Axioskop 2 plus; Zeiss, Thornwood, NJ). Photo-
micrographs were taken under the ×40 objective using an AxioCam
digital camera and AxioVision 4.0 software (Zeiss).
Results
Infection of Mouse Mammary Cells Using
a Pseudotyped Lentivirus
Keratin 19 (K19) is expressed selectively in epithelial cells in sev-
eral organs including the mammary gland and pancreas [17]. K19 is
a general epithelial cell marker in the mammary gland, although it
might also be expressed in mammary bipotential progenitor cells that
give rise to both more mature epithelial cells and myoepithelial cells
[22,23]. It is not expressed in myoepithelial cells and seems to be
absent in mammary stem cells [23]. Transgenic mice expressing tva
from the K19 promoter has been reported [17]. TVA produced in
transgenic K19-tva mice confers susceptibility to RCAS infection
in pancreatic ductal cells [17]. Using immunohistochemical staining
for TVA, we found that TVA was produced in nearly all epithelial
cells in the ducts and in the body cells of terminal end buds in the
mammary glands of 7-week-old K19-tva transgenic mice (Figure 1,
B and E ). This is in contrast to the patchy pattern of expression in
MMTV-tva transgenic mice (Figure 1, C and F ) [5].
To test whether ALSV env–pseudotyped lentivirus could infect TVA+
mammary cells, we first ascertained that it could infect TVA+ primary
mouse mammary cells ex vivo. A total of 5 × 106 infectious units (IU)
of HIV(ALSV)-GFP were added to primary cells 1 day after prepa-
ration from the mammary glands of K19-tva mice. Three days later,
GFP was observed in approximately 10% of the cells (data not
shown), demonstrating that TVA+ primary mammary cells in culture
are susceptible to infection by pseudotyped lentivirus. As expected,
this virus did not infect mammary cells prepared from nontransgenic
mice or mammary tumor cells prepared from transgenic mice that ex-
pressed neu (ErbB2) from the MMTV promoter [24] (data not shown).
To determine whether a pseudotyped lentiviral vector could infect
mammary epithelial cells in vivo, we intraductally injected 104 IU of
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HIV(ALSV)-GFP viral concentrate into the left #2, 3, and 4 mam-
mary glands in six female K19-tva transgenic mice at 11 weeks of
age. Five days after injection, we collected the infected glands, made
single-cell suspensions, and used flow cytometry to quantify the
number of GFP+ cells. (Sample FACS plots are shown in Figure 1,
G–I .). We found that 0.1 ± 0.07% of the cells (approximately
400 cells per gland) were positive for GFP (Figure 1J ). (Because
infected cells may proliferate or die during these 5 days, the initial
number of infected cells may be more or less.) This result demon-
strates that the ALSV-pseudotyped lentivirus can infect mammary
cells in tva transgenic mice.
To compare the infection efficiency of the HIV(ALSV) and RCAS
vectors, we also injected the contralateral three glands in all six mice
with an equivalent titer of RCAS-GFP viral concentrate and quanti-
fied the fraction of GFP+ cells (Figure 1I ). The percentage of GFP+
cells in RCAS-GFP–infected glands was 0.06 ± 0.05%, not signifi-
cantly different (P = .26) from that achieved by the pseudotyped len-
tiviral vector (Figure 1J ). Two additional, similar experiments gave an
equivalent result, suggesting that at the level of viral dosage tested,
HIV(ALSV) and RCAS vectors are similar in their ability to infect
mammary epithelial cells in adult K19-tva transgenic mice.
To verify the tissue specificity of infection in K19-tva transgenic
mice using the intraductal injection method, we intraductally in-
jected 105 IU of HIV(ALSV)-GFP viral concentrate into all #2, 3,
and 4 mammary glands in four female K19-tva transgenic mice at
14 weeks of age. Four days after injection, we collected the mammary
glands, hearts, intestines, lungs, pancreas, skins, and salivary glands
of injected mice. We confirmed by immunohistochemistry that HIV
(ALSV)-GFP could infect mammary cells in vivo; only cells bordering
the ductal lumen were observed to produce GFP (Figure 1K ), which
correlates with the pattern of TVA+ cells (Figure 1A). We did not
detect GFP+ cells in all the other organs examined (data not shown),
including skin and salivary gland that have been reported to express
tva in this transgenic mouse line [17]. Therefore, infection by the
HIV(ALSV) vector introduced by intraductal injection is restricted
to TVA-producing cells of the mammary glands.
Early Mammary Lesions Formed by HIV(ALSV)-PyMT
Having shown that HIV(ALSV) could infect murine mammary
cells in vivo, we next investigated the suitability of pseudotyped lenti-
viral vectors for inducing mammary tumors. PyMT is a potent trans-
forming oncogene whose gene product activates multiple signaling
pathways including those mediated by Src, Shc, and phosphatidylino-
sitol 3-kinase, and it has been used to induce mammary tumors
[5,25,26]. Therefore, we tested whether infection by HIV(ALSV)-
PyMT (Figure W1) could transform mammary cells in vivo. We intra-
ductally injected 103 IU of HIV(ALSV)-PyMT into both #4 mammary
glands of three female K19-tva transgenic mice (9–11 weeks old), har-
vested infected glands at 30 days after injection, and examined their
paraffin sections for histopathologic changes by H&E. We observed
atypical hyperplasia and ductal carcinoma in situ–like lesions in five
of six infected mammary glands (Figure 2A); solid cell proliferation
with central necrosis was also observed in one infected gland. We
confirmed that PyMTwas produced in these lesions by immunohisto-
chemical staining for the HA-tag (Figure 2B). As expected, HA staining
was absent in the normal-appearing ducts adjacent to these lesions
(Figure 2B, blue arrows), and neither early lesions nor HA staining
was observed in noninjected glands (Figure 2, C and D). Therefore,
we conclude that PyMT delivered by this pseudotyped lentiviral vector
can induce premalignant changes in tva transgenic mice.
Tumor Formation by HIV(ALSV)-PyMT Virus
Having demonstrated the formation of early lesions after infection
by HIV(ALSV)-PyMT, we used this vector to induce tumors in K19-
tva transgenic mice. We injected 21 adult mice with HIV(ALSV)-
PyMT (103 IU/gland, six glands/mouse). Injection success rate as
determined by visualization of the ductal tree immediately after injec-
tion varied from 0/6 to 6/6 glands per mouse; only the 13 mice with
two or more successful injections were monitored for tumor forma-
tion. Ten of these mice developed palpable tumors within 1 year in
at least one gland, and another one died after 9 months for nontumor
reasons. Median tumor latency was 3.3 months (Figure 3A). All nine
successfully injected glands in the remaining two mice were collected
after 1 year and examined for histopathologic changes, but no early
lesions were identified and no HA tag could be found in at least five
representative sections prepared from each of these nine glands, sug-
gesting that the infected cells had either died or failed to express PyMT
from the provirus. In the tumors that developed in injected glands,
PyMT could be detected in the tumor cells by immunohistochemical
staining (Figure 4A), and tumors were never found in noninjected
gland #1 or #5, nor in noninjected control K19-tva transgenic mice.
Therefore, we conclude that pseudotyped lentiviral vectors can be used
to introduce oncogenes for modeling breast cancer in mice.
The relatively long latency in these mice suggested that these tumors
were clonal in origin. To determine their clonality, DNA prepared
from six tumors were digested with BamHI to generate a unique frag-
ment for each proviral integration in the cellular genome. This frag-
ment was subsequently detected by a radioactively labeled PyMT
probe (Figure 3C). Five tumors yielded single bands (Figure 3B), dem-
onstrating their clonal origin. The sixth tumor harbored two insertion
sites (Figure 3B, lane 1). We cannot conclude whether this tumor
originated from a single cell infected by two viruses or from two singly
infected cells. Because the two bands are similar in intensity, we
suspect that this tumor arose from a doubly infected cell. Double
Figure 1. Lentiviral infection in K19-tva transgenic mice. (A–F) Immunohistochemical staining for TVA in mammary gland sections from
pubertal K19-tva transgenic mice. Staining results of both ducts and terminal end buds (TEBs) are shown. Genotypes are indicated at
the top. Scale bar, 20 μm. (G–I) The left #2 to 4 mammary glands of six adult K19-tva transgenic mice were injected with HIV(ALSV)-GFP
(104 IU/gland), and an equal amount of RCAS-GFPwas injected into each of the contralateral glands. Infection efficiency was determined
by FACS for GFP 5 days after injection. Shown are representative FACS plots of mammary cells from uninjected (G), HIV(ALSV)-GFP–
injected (H), and RCAS-GFP–injected (I) K19-tva transgenic mice. No phycoerythrin (PE) was added to the cells; the PE channel (Y-axis)
was used to segregate autofluorescing cells (high in both PE and GFP channels) from GFP+ cells (high GFP and no PE). (J) Quantitation
of GFP+ cells 5 days after injection (n = 6 mice, mean ± SD). (K) Immunohistochemical staining for GFP in mammary gland sections
from adult K19-tva transgenic mice harvested 4 days after injection of HIV(ALSV)-GFP (105 IU) into the ductal lumen. Arrows indicate
positively stained cells. Scale bar, 20 μm.
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infection occurs in TVA+ mammalian cells, including mammary epithe-
lial cells, using RCAS vectors [27] (W. Bu, unpublished observations).
Characterization of Mammary Tumors Induced by
HIV(ALSV)-PyMT
Histologically, HIV(ALSV)-PyMT–induced mammary tumors were
predominantly papillary adenomyoepithelioma/carcinomas, with occa-
sional foci of squamous cell metaplasia in 7 of 16 cases (Figure 3, D–
F ). The tumors were highly proliferative; 9.9 ± 2.5% of tumor cells
incorporated 5-bromo-2′-deoxyuridine (BrdU) 2 hours after BrdU in-
jection (n = 5), much higher than the 0.8 ± 0.5% seen in epithelial
cells from normal mammary glands of adult K19-tva mice (n = 3, data
not shown).
Using immunohistochemical staining for the epithelial cell marker
keratin 8 and the myoepithelial cell markers keratin 5, p63, and
α-smooth muscle actin, we found that HIV(ALSV)-PyMT–induced
tumors were composed of both luminal cells and myoepithelial cells
(Figures 4, C–D, and W2). Using coimmunofluorescent staining, we
found positive HA staining in many of the keratin 14+ myoepithelial
tumor cells (Figure 4, E–G ), indicating that they were progeny of the
HIV(ALSV)-PyMT–infected cells. As expected, HA was also de-
tected in the keratin 8+ luminal cells, which comprised the bulk of
the tumor mass (data not shown). The cellular heterogeneity of these
tumors strongly suggests an origin in bipotential progenitor cells,
although we cannot rule out the remote possibility that the initial
infection may have occurred in a terminally differentiated epithelial
cell that in the course of oncogenesis dedifferentiated, producing
progeny in both lineages.
The finding that HIV(ALSV)-PyMT–induced tumors contain
mixed differentiated cell populations is in contrast to the poorly dif-
ferentiated tumors arising in MMTV-PyMT transgenic mice [26],
possibly reflecting the consequences of oncogene expression in the
developing mammary gland in these transgenic mice. In this respect,
our lentivirus-induced tumors are reminiscent of tumors initiated by
RCAS-PyMT in MMTV-tva transgenic mice, which also contain
mixed cell populations [5]. However, RCAS-PyMT–induced tumors
in MMTV-tva transgenic mice lacked squamous metaplasia. In addi-
tion, whereas most of these RCAS-PyMT–induced tumors produced
ERα (Z. Du and Y. Li, unpublished observations), tumors induced
by HIV(ALSV)-PyMT lacked ERα (Figure 4B). To test whether
these differences may have been caused by the difference in the tva
transgene or the genetic background of the two mouse lines, by in-
traductal injection, we infected 12 K19-tva transgenic mice with
RCAS-PyMT (105 IU per gland, two or three glands per mouse). Pal-
pable tumors developed within 4 to 6 weeks in all infected mice,
comparable to the latency observed in MMTV-tva transgenic mice
[5]. Like tumors arising in RCAS-PyMT–infected MMTV-tva trans-
genic mice, RCAS-PyMT–induced tumors arising in K19-tva trans-
genic mice were adenomyoepithelioma/carcinomas containing both
Figure 2. Early lesions in HIV(ALSV)-PyMT–injected mammary glands. Three adult K19-tva transgenic mice were intraductally injected
with 103 IU HIV(ALSV)-PyMT. Mice were killed 30 days after injection, and mammary glands were sectioned and stained by H&E for
histologic examination. One or more early lesions were observed in all mice (red arrow) (A). Adjacent sections were examined for
HA-tagged PyMT by immunohistochemistry (B); many cells are positively stained (red arrow). Note that HA was not detected in adjacent
normal-appearing ducts (blue arrows). Sections from noninjected glands had neither early lesions (C) nor cells producing PyMT (D).
Scale bar, 100 μm.
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Figure 3. Tumor induction by HIV(ALSV)-PyMT. K19-tva transgenic mice were intraductally injected with 103 IU of HIV(ALSV)-PyMT into
the #2 to 4 mammary glands. (A) Kaplan–Meier curve showing tumor-free survival of infected mice (n = 13). One mouse died of natural
causes and was censored at 9 months after injection. (B–C) Clonality analysis of HIV(ALSV)-PyMT virus–induced mammary tumors in
K19-tva transgenic mice. Genomic DNA from 6 HIV(ALSV)-PyMT–induced tumors was subjected to Southern blot analysis after digestion
with BamHI (B); molecular weights are indicated (left). A diagram of the HIV(ALSV)-PyMT provirus is shown (C); the radioactive probe
was transcribed from the indicated 2.4-kb BamHI–EcoRV fragment. (D–G) Representative photomicrographs showing both papillary
adenomyoepithelioma/carcinoma (D and E) and squamous cell–like (F) regions of tumors induced by HIV(ALSV)-PyMT. For comparison,
an H&E–stained section from a tumor induced by RCAS-PyMT in a K19-tva transgenic mouse is shown (G); RCAS-PyMT–induced tumors
were reminiscent of papillary adenomyoepithelioma/carcinomas. Scale bar, 50 μm.
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epithelial and myoepithelial lineages (Figure 3G ), produced ERα in 6
of 13 tumors, and had no squamous metaplasia (data not shown). To
examine whether differences in PyMT expression levels could
explain the differences between HIV- and RCAS-PyMT–induced
tumors, we used Western blot analysis to assay samples from seven
tumors induced by each vector for relative levels of PyMT. We noted
great variability of PyMT levels between individual tumors (Fig-
ure 4H ). However, there was no consistent trend toward higher
PyMT levels with one vector that could easily explain our observed
differences. Therefore, even in the same tva transgenic line, differ-
ences in ER status and squamous metaplasia existed between tumors
induced by HIV(ALSV)-PyMT and those induced by RCAS-PyMT.
Figure 4. Characterization of HIV(ALSV)-PyMT–induced mammary tumors. Paraffin sections from HIV(ALSV)-PyMT–induced tumors were
analyzed by immunohistochemistry for HA-tagged PyMT (A), ERα (B), keratin 8 (C), and keratin 5 (D). In each case, the insert shows a
representative staining of a normal mammary gland section. Scale bar, 25 μm; in all sections, n = 15 tumors. (E–G) HIV(ALSV)-PyMT–
induced tumors contain myoepithelial cells of infected cell origin. Representative photomicrographs of coimmunofluorescent staining of
paraffin sections from HIV(ALSV)-PyMT–induced mammary tumors for cells producing HA-tagged PyMT (E) and the myoepithelial marker
keratin 14 (F). Arrows indicate myoepithelial cells positive for both keratin 14 and PyMT (G). Insert: negative HA staining in a tumor from
an MMTV–Wnt-1 transgenic mouse. Scale bar, 25 μm; n = 5. (H) Western blot analysis of PyMT in tumors. Sample lysates from tumors
induced by the indicated PyMT-expressing vectors were probed for the HA tag in PyMT (top panel), with β-actin serving as a loading
control (bottom panel). Quantitation of relative HA signal intensity (corrected for total protein) is indicated below each lane
(arbitrary units).
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Discussion
We here demonstrate that pseudotyped lentiviral vectors can infect
mouse mammary cells in vivo and can serve as a vehicle for tumor
induction. This method shares the advantages of the RCAS-TVA
technology [28], namely, oncogene expression at a specific time,
tumor initiation in a background of normal cells, targeting of specific
populations of cells for oncogenesis through the choice of a promoter
regulating tva expression, and relative ease of testing different puta-
tive oncogenes for a role in tumor formation. However, the HIV
(ALSV) vector is more suitable for infecting nondividing cells and
can carry a much larger DNA insert, allowing the introduction of
two or more genes in one vector. This larger cloning capability is
especially useful for testing oncogenic collaboration.
Because cell proliferation is low in adult mammary glands, we anti-
cipated that HIV(ALSV) vectors would infect more cells in tva trans-
genic mice than RCAS viruses of comparable titers. However, we only
saw a trend toward higher infection using HIV(ALSV)-GFP that did
not reach significance (Figure 1). It is likely that, at the viral titer used,
we did not saturate the number of TVA+ proliferating cells in the gland
with the RCAS virus. Indeed, the 0.8% proliferation rate in the mam-
mary epithelium in adult K19-tva transgenic mice is still 13-fold higher
than the 0.06% infection efficiency observed with the RCAS vector
(Figure 1J ). The use of higher titer viral stocks may demonstrate the
higher number of mammary cells in vivo susceptible to infection by
HIV(ALSV) relative to RCAS viruses, as has been shown in cultured
epithelial cells and fibroblasts [16].
Introduction of PyMT to mammary cells using the HIV(ALSV)-
PyMT vector resulted in papillary adenomyoepithelioma/carcinomas
quite similar to those arising in RCAS-PyMT–infected mammary
glands (Figure 3) but very different from those arising in MMTV-
PyMT transgenic mice [26]. Although the tumors induced by the
RCAS and HIV(ALSV) vectors share many similarities, one differ-
ence between the tumors is the presence of occasional foci resembling
squamous cell metaplasia in HIV(ALSV)-PyMT–initiated, but not in
RCAS-PyMT–initiated tumors (Figure 3). In addition, the tumors
induced by these vectors display different ER status. We do not know
the reasons for these differences. One possible explanation for the
presence of regions of squamous differentiation is that the HIV virus
infected a broader range of cells, including those with greater devel-
opmental plasticity.
The tumor latency was much longer in mice infected by HIV
(ALSV)-PyMT (Figure 3A) than in mice infected by RCAS-PyMT
[5]. The longer latency in the former mice is likely due to the much
smaller viral dosage (103 vs 105 IU) used to infect the mice, leading
to the infection of presumably a few cells (vs several thousand cells in
RCAS-PyMT–infected mice). Whereas PyMT seems to be sufficient
to transform a subset of somatic mammary cells in mice based on the
extremely short latency (median = 2 weeks) in MMTV-tva mice
infected by RCAS-PyMT (107 IU per gland, leading to the infection
of approximately 3000 cells [5]), other mammary cells may not be
converted to malignancy after PyMT is expressed because a much
longer latency (median = 2 months) was observed when 1000-fold
less RCAS-PyMT virus was used to infect the same line of mice
(Z. Du and Y. Li, unpublished observations). Therefore, the HIV
(ALSV)-PyMT–injected mice that either developed tumors very
late or never developed tumors might have received infection in only
a small number of the mammary cells that were more resistant
to tumor induction by PyMT. In addition, the longer latency in
HIV(ALSV)-PyMT–infected mice may also be caused by the
down-regulation of the cytomegalovirus promoter driving PyMT
expression in the lentiviral vector. The cytomegalovirus promoter,
although apparently more active in cultured cells than the RCAS
LTR, has been shown to be silenced in hematopoietic and other tis-
sues in mice [29,30].
In conclusion, this work demonstrates that lentiviral vectors can be
used as a vehicle to introduce oncogenes in specific TVA+ mouse cells
for cancer induction and expands the versatility of the TVA technol-
ogy for functional in vivo testing of candidate genes, especially larger
genes that cannot be expressed from RCAS. This vector system may
also be better suited for the introduction of oncogenes into quiescent
stem cells or highly differentiated postmitotic cells.
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Figure W1. ALSV env-pseudotyped lentiviral constructs. Constructs used for generation of HIV(ALSV)-GFP (top) and HIV(ALSV)-PyMT
(bottom). CMV indicates cytomegalovirus promoter; FLAP, HIV flap region; GFP, green fluorescent protein; ψ, packaging sequence;
PyMT, HA-tagged polyoma middle T antigen; RRE, retroviral response element; U3, R, and U5, HIV long tandem repeat; Ubi C, ubiquitin
C promoter. Lengths are not drawn to scale.
Figure W2. Keratin expression in HIV(ALSV)-PyMT–induced mammary tumors. Paraffin sections from HIV(ALSV)-PyMT–induced tumors
were analyzed by immunohistochemistry for keratin 8 (top) and keratin 5 (bottom). Scale bar, 50 μm.
